RxDoctor Payments Data

Meredith Sagal

Family · Hunt Valley, MDNPI 1932644457

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Johnson & Johnson at 48.4% of the total. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$81,832in general payments, 2019–2025

Across 936 payments — averaging $87.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$40K
  • E.r. Squibb & Sons, L.L.C.$15K
  • Galderma Laboratories, L.p.$10K
  • AbbVie$3K
  • Lilly USA, LLC$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • plus $11K from 24 others

What the payments were for

  • Consulting fees$4,2965%
  • Speaking & faculty fees$47,46658%
  • Travel & lodging$5,2486%
  • Food & beverage$23,82929%
  • Education$9921%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,832 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$176,747
Medicare patients
721
Services billed
3,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab13$48,067
JubliaEfinaconazole12$10,730
Clobetasol Propionate44$4,128
Fluorouracil37$2,092
Ketoconazole79$1,826
Tacrolimus11$1,608
Clindamycin Phosphate37$1,091
Metronidazole25$1,043
Fluocinonide36$982
Betamethasone Dipropionate20$803
Triamcinolone Acetonide120$760
Doxycycline Monohydrate30$583
Imiquimod14$576
Spironolactone20$481
Ciclopirox17$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$335$10,73012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Hunt Valley

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →